Microtubule-binding natural products for cancer therapy

Planta Medica

Volumn 76, Issue 11, 2010, Pages 1037-1043

  Yue, Qing Xi ^a,b   Liu, Xuan ^a   Guo, De An ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

antiangiogenisis; cancer; drug resistance; marine sources; microtubulebinding agents; natural products

Indexed keywords

ABC TRANSPORTER; ALPHA TUBULIN; BETA TUBULIN; COLCHICINE; COMBRETASTATIN A4; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; HALICHONDRIN B; IXABEPILONE; LAULIMALIDE; MICROTUBULE PROTEIN; N ACETYLCOLCHINOL PHOSPHATE; NATURAL PRODUCT; NAVELBINE; PACLITAXEL; TALTOBULIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CATHARANTHUS ROSEUS; CYTOTOXICITY; DRUG BINDING SITE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG TRANSPORT; ENDOTHELIUM CELL; HUMAN; LUNG CANCER; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BRIDGED COMPOUNDS; CLINICAL TRIALS AS TOPIC; COLCHICINE; EPOTHILONES; HUMANS; MICROTUBULES; NEOPLASMS; TAXOIDS; TUBULIN MODULATORS; VINCA ALKALOIDS;

VINCA;

EID: 77955080328     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1250073     Document Type: Review

References (90)

1. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009 59 365-378
2. Kinghorn A D., Su B N., Jang D S., Chang L C., Lee D, Gu J Q., Carcache-Blanco E J., Pawlus A D., Lee S K., Park E J., Cuendet M, Gills J J., Bhat K, Park H S., Mata-Greenwood E, Song L L., Jang M, Pezzuto J M. Natural inhibitors of carcinogenesis. Planta Med 2004 70 691-705
3. Bailly C. Ready for a comeback of natural products in oncology. Biochem Pharmacol 2009 77 1447-1457
4. Risinger A L., Giles F J., Mooberry S L. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009 35 255-261
5. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008 60 165-170
6. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater 2007 3 413-438 (Pubitemid 46865787)
7. Jordan M A., Hadfield J A., Lawrence N J., McGown A T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998 18 259-296
8. Jordan M A., Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007 7 730-742
9. Jordan M A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticaner Agents 2002 2 1-17
10. Singh P, Rathinasamy K, Mohan R, Panda D. Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life 2008 60 368-375
11. Altmann K H., Gertsch J. Anticancer drugs from nature natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007 24 327-357
12. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003 8 413-450
13. Jordan M A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004 4 253-265
14. Chaplin D J., Dougherty G J. Tumor vasculature as a target for cancer therapy. Br J Cancer 1999 80 57-64
15. Tozer G M., Kanthou C, Baguley B C. Disrupting tumour blood vessels. Nat Rev Cancer 2005 5 423-435
16. Schwartz E L. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009 15 2594-2601
17. Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat 2006 9 74-86
18. Kanthou C, Tozer G M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009 90 284-294
19. Ahmed B, Van Eijk L I., Bouma-Ter Steege J C., Van Der Schaft D W., Van Esch A M., Joosten-Achjanie S R., Lambin P, Landuyt W, Griffioen A W. Vascular targeting effect of combrestastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003 105 20-25
20. Rustin G J., Shreeves G, Nathan P D., Gaua A, Ganesan T S., Wang D, Boxall J, Poupard L, Chaplin D J., Stratford M R., Balkissoon J, Zweifei M. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010 102 1355-1360
21. McKeage M J., Baguley B C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010 116 1859-1871
22. Kavellaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010 10 194-204
23. Fojo A T., Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007 18 v3-v8
24. Fojo A T., Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005 32 S3-S8
25. Gottesman M M., Pastan I, Ambudkar S V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996 6 610-617
26. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005 5 457-468
27. Seeger M A., van Veen H W. Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 2009 1794 725-737
28. Kamath K, Wilson L, Cabral F, Jordan M A. Beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005 280 12902-12907
29. Stengel C, Newman S P., Leese M P., Potter B V., Reed M J., Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 2010 102 316-324
30. Davis P D., Dougherty G J., Blakey D C., Galbraith S M., Tozer G M., Holder A L., Naylor M A., Nolan J, Stratford M R., Chaplin D J., Hill S A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002 62 7247-7253
31. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003 63 1534-1537
32. LoRusso P M., Gadgeel S M., Wozniak A, Barge A J., Jones H K., DelProposto Z S., DeLuca P A., Evelhoch J L., Boerner S A., Wheeler C. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008 26 159-167
33. Hinnen P, Eskens F A. L. M. Vascular disrupting agents in clinical development. Br J Cancer 2007 96 1159-1165
34. Vincent L, Kermani P, Young L M., Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin D J., Bohlen P, Chaplin D J., May C, Rafii S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005 115 2992-3006
35. Gupta S, Bhattacharyya B. Antimicrotubular drugs binding to Vinca domain of tubulin. Mol Cell Biochem 2003 253 41-47
36. Johnson I S., Armostrong J G., Gorman M, Burnett Jr J P. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 1967 23 1390-1427
37. Jordan M A., Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991 51 2212-2222
38. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill B T., Taraboletti G. Anti-angiogenic, vascular-disrupting and antimetastatic activities of vinflunine, the latest Vinca alkaloid in clinical development. Eur J Cancer 2006 42 2821-2832
39. Holwell S E., Hill B T., Bibby M C. Anti-vascular effects of vinflunine in the Mac 15A transplantable adenocarcinoma model. Br J Cancer 2001 84 290-295
40. Johnson P, Geldart T, Fumoleau P, Pinel M C., Nguyen L, Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest Drugs 2006 24 223-231
41. Yun-San Yip A, Yuen-Yuan Ong E, Chow L W. Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 2008 17 583-591
42. Bennouna J, Delord J P., Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008 14 1625-1632
43. Kruczynski A, Hill B T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001 40 159-173
44. Kingston D G. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009 72 507-515
45. Anderson H J., Coleman J E., Andersen R J., Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 1997 39 223-226
46. Simoni D, Lee R M., Durrant D E., Chi N W., Baruchello R, Rondanin R, Rullo C, Marchetti P. Versatile synthesis of new cytotoxic agents structurally related to hemiasterlins. Bioorg Med Chem Lett 2010 20 3431-3435
47. Loganzo F, Discafani C M., Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchysky M S., Fojo T, Nieman J A., Ayral-Kaloustian S, Zas A, Andersen R J., Greenberger L M. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003 63 1838-1845
48. Niu C, Ho D M., Zask A, Ayral-Kaloustian S. Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett 2010 20 1535-1538
49. Blagosklonny M V., Fojo T. Molecular effects of paclitaxel: myths and reality (A critical review). Int J Cancer 1999 83 151-156
50. Francis P A., Kris M G., Rigas J R., Grant S C., Miller V A. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 1995 12 S163-S172
51. Buey R M., Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu J M., Diaz J F. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol 2005 12 1269-1279
52. Elie-Caille C, Severin F, Helenius J, Howard J, Muller D J., Hyman A A. Straight GDP-tubulin protofilaments form in the presence of Taxol. Curr Biol 2007 17 1765-1770
53. Andru J M., Bordas J, Diaz J F., Garcia de Ancos J, Gil R, Medrano F J., Nogales E, Pantos E, Towns-Andrews E. Low resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of Taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules. J Mol Biol 1992 226 169-184
54. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005 6 229-239
55. McGrogan B T., Gilmartin B, Carney D N., McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008 1785 96-132
56. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009 136 21-29
57. Oza A M. Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002 243 103-115
58. Galmarini C M., Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery M C., Paesmans M, Larsimont D, Piccart M J., Di Leo A, Dumontet C. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008 14 4511-4516
59. Shalli K, Brown I, Heys S D., Schofield A C. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005 19 1299-1301
60. Perez E A. Novel enhanced delivery taxanes: an update. Semin Oncol 2007 34 1-5
61. Nyman D W., Campbell K J., Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins M J., Von Hoff D D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005 23 7785-7793
62. Gradishar W J., Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, Oshaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005 23 7794-7803 (Pubitemid 46657376)
63. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne J P., Beliveau R. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008 324 1064-1072
64. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996 49 560-563 (Pubitemid 26235665)
65. Goodin S. Novel cytotoxic agents: epothilones. AM J Health Syst Pharm 2008 65 S10-S15
66. Villanueva C, Vuillemin A T., Demarchi M, Bazan F, Chaigneau L, Pivot X. Ixabepilone: a new active chemotherapy in the treatment of breast cancer. Womens Health 2009 5 115-121
67. Trivedi M, Budihardjo I, Loureiro K, Reid T R., Ma J D. Epothelione: a novel class of microtubulie-stabilizing drugs for the treatment of cancer. Future Oncol 2008 4 483-500
68. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007 18 v9-v15
69. Morris P G., Fornier M N. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008 14 7167-7172
70. Gollner A, Altmann K H., Gertsch J, Mulzer J. The laulimalide family: total synthesis and biological evaluation of neolaulimalide, isolaulimalide, laulimalide and a nonnatural analogue. Chemistry 2009 15 5979-5997
71. Clark E A., Hills P M., Davidson B S., Wender P A., Mooberry S L. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 2006 3 457-467
72. Lu H, Murtagh J, Schwartz E L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 2006 69 1207-1215
73. Mooberry S L., Tien G, Hernandez A H., Plubrukarn A, Davidson B S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999 59 653-660
74. Liu J, Towle M J., Cheng H, Saxton P, Reardon C, Wu J, Murphy E A., Kuznetsov G, Johannes C W., Tremblay M R., Zhao H, Pesant M, Fang F G., Vermeulen M W., Gallagher Jr B M., Littlefield B A. In vitro and in vivo anticancer activities of synthetic ()-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007 27 1509-1518
75. Johnson T A., Tenney K, Cichewicz R H., Morinaka B I., White K N., Amagata T, Subramanian B, Media J, Mooberry S L., Valeriote F A., Crews P. Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties. J Med Chem 2007 50 3795-3803
76. Mooberry S L., Randall-Hlubek D A., Leal R M., Hegde S G., Hubbard R D., Zhang L, Wender P A. Microtubule-stabilizing agents based on designed laulimalide analogues. Proc Natl Acad Sci USA 2004 101 8803-8808
77. West L M., Northcote P T., Battershill C N. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000 65 445-449
78. Hamel E, Day B W., Miller J H., Jung M K., Northcote P T., Ghosh A K., Curran D P., Cushman M, Nicolaou K C., Paterson I, Sorensen E J. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006 70 1555-1564
79. Gaitanos T N., Buey R M., Daz J F., Northcote P T., Teesdale-Spittle P, Andreu J M., Miller J H. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 2004 64 5063-5067
80. Wilmes A, Bargh K, Kelly C, Northcote P T., Miller J H. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 2007 4 269-280
81. Huzil J T., Chik J K., Slysz G W., Freedman H, Tuszynski J, Taylor R E., Sackett D L., Schriemer D C. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 2008 378 1016-1030
82. Evans D A., Welch D S., Speed A W., Moniz G A., Reichelt A, Ho S. An aldol-based synthesis of (+)-peloruside A, a potent microtubule stabilizing agent. J Am Chem Soc 2009 131 3840-3841
83. Singh A J., Xu C X., Xu X, West L M., Wilmes A, Chan A, Hamel E, Miller J H., Northcote P T., Ghosh A K. Peloruside B, a potent anti-tumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis and bioactivity. J Org Chem 2010 75 2-10
84. Tinley T L., Randall-Hlubek D A., Leal R M., Jackson E M., Cessac J W., Quada Jr J C., Hemscheidt T K., Mooberry S L. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003 63 3211-3220
85. Risinger A L., Jackson E M., Polin L A., Helms G L., LeBoeuf D A., Joe P A., Hopper-Borge E, Luduea R F., Kruh G D., Mooberry S L. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 2008 68 8881-8888
86. Buey R M., Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu J M., Diaz J F. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol 2005 12 1269-1279
87. Risinger A L., Mooberry S L. Taccalonolides: novel microtubule stabilizers with clinical potential. Cancer Lett 2010 291 14-19
88. Jackson K L., Henderson J A., Phillips A J. The halichondrins and E7389. Chem Rev 2009 109 3044-3079
89. Jimeno A. Eribulin: rediscovering tubulin as an anticancer target. Clin Cancer Res 2009 15 3903-3905
90. Smith J A., Wilson L, Azarenko O, Zhu L, Lewis B M., Littlefield B A., Jordan M A. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010 49 1331-1337